SPONSOR
Cabaletta Bio
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Cabaletta Bio is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Systemic Sclerosis, Scleroderma, Systemic Lupus Erythematosus, Lupus Nephritis.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Cabaletta Bio
How many clinical trials has Cabaletta Bio sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Cabaletta Bio, of which 2 are actively recruiting participants. These trials cover conditions including Systemic Sclerosis, Scleroderma, Systemic Lupus Erythematosus. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Cabaletta Bio research focus on?
Cabaletta Bio clinical trials span Systemic Sclerosis, Scleroderma, Systemic Lupus Erythematosus, Lupus Nephritis. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Cabaletta Bio clinical trial?
To participate in a Cabaletta Bio trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Cabaletta Bio trials with current recruitment status updated daily.
Clinical Trials by Cabaletta Bio
NCT06328777 Phase 1, Phase 2
Recruiting
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Systemic Sclerosis
NCT06121297 Phase 1, Phase 2
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology